Opportunities for Conventional and In Situ Cancer Vaccine Strategies and Combination with Immunotherapy for Gastrointestinal Cancers, A Review
Open Access
Abstract
Survival of gastrointestinal cancer remains dismal, especially for metastasized disease. For various cancers, especially melanoma and lung cancer, immunotherapy has been proven to confer survival benefits, but results for gastrointestinal cancer have been disappointing. Hence, there is substantial interest in exploring the usefulness of adaptive immune system education with respect to anti-cancer responses though vaccination. Encouragingly, even fairly non-specific approaches to vaccination and immune system stimulation, involving for instance influenza vaccines, have shown promising results, eliciting hopes that selection of specific antigens for vaccination may prove useful for at least a subset of gastrointestinal cancers. It is widely recognized that immune recognition and initiation of responses are hampered by a lack of T cell help, or by suppressive cancer-associated factors. In this review we will discuss the hurdles that limit efficacy of conventional cancer therapeutic vaccination methods (e.g., peptide vaccines, dendritic cell vaccination). In addition, we will outline other forms of treatment (e.g., radiotherapy, chemotherapy, oncolytic viruses) that also cause the release of antigens through immunogenic tumor cell death and can thus be considered unconventional vaccination methods (i.e., in situ vaccination). Finally, we focus on the potential additive value that vaccination strategies may have for improving the effect immunotherapy. Overall, a picture will emerge that although the field has made substantial progress, successful immunotherapy through the combination with cancer antigen vaccination, including that for gastrointestinal cancers, is still in its infancy, prompting further intensification of the research effort in this respect.Keywords
This publication has 172 references indexed in Scilit:
- A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancerCancer Medicine, 2019
- Combination therapy with PD-1 or PD-L1 inhibitors for cancerInternational Journal of Clinical Oncology, 2019
- Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancerCancer Immunology, Immunotherapy, 2019
- Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related CancerJAMA Oncology, 2019
- In situ vaccination: Harvesting low hanging fruit on the cancer immunotherapy treeWIREs Nanomedicine and Nanobiotechnology, 2018
- Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinomaInvestigational New Drugs, 2017
- Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T‐cell activationEuropean Journal of Immunology, 2013
- Mammaglobin-A cDNA vaccination of breast cancer patients induces antigen-specific cytotoxic CD4+ICOShi T cellsBreast Cancer Research and Treatment, 2012
- DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8+ T-cell responses and increases PSA doubling timeCancer Immunology, Immunotherapy, 2012
- Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunityCancer Immunology, Immunotherapy, 2008